Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|20|3612-3621

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.20, 2015-10, pp. : 3612-3621

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 179-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 193-196

John Wiley & Sons Inc

Access to resources Recommend Favorite

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 967-969

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 37-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite